Platform Trials

Haitao Pan () and Ying Yuan ()
Additional contact information
Haitao Pan: St. Jude Children’s Research Hospital, Department of Biostatistics
Ying Yuan: The University of Texas MD Anderson Cancer Center, Department of Biostatistics

Chapter Chapter 9 in Bayesian Adaptive Design for Immunotherapy and Targeted Therapy, 2023, pp 201-262 from Springer

Abstract: Abstract Traditional phase II clinical trial designs were developed mainly for evaluating candidate treatments in a one-treatment-at-a-time manner. With tremendous advances in biomedical research, a number of candidate drugs are produced and discovered at an unprecedented speed. This makes the traditional one-treatment-at-a-time phase II trial paradigm cumbersome and grossly inefficient. Platform trials, also known as multi-arm multi-stage trials, provide an efficient way to screen a large number of candidate drugs and quickly identify promising ones for the next phase of development. In this chapter, several platform trial designs are introduced to illustrate this approach. These designs are highly flexible and adaptive, allowing dropping inefficient treatments and adding new candidate treatments during the course of the trial.

Date: 2023
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-981-19-8176-0_9

Ordering information: This item can be ordered from
http://www.springer.com/9789811981760

DOI: 10.1007/978-981-19-8176-0_9

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().